# Mechanism of Ocrelizumab in B-Cell Depletion ## How does ocrelizumab target CD20-positive B cells to drive B-cell depletion? Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets. # Abstract Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors. B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability. ## Methods We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. Records from Elicit search - **n = 200** - Papers screened using: Mechanistic Focus on CD20/B-cells, Specific Depletion Mechanisms, Study Type and Mechanistic Data, Mechanistic Content Present, CD20/B-cell Relevance, Study Rigor and Detail - **n = 200** Papers screened out - **n = 190** - Papers included for extraction - **n = 10** ## Paper search We performed a semantic search across over 138 million academic papers from the Elicit search engine. ## Screening We screened in sources based on their abstracts that met these criteria: - **Mechanistic Focus on CD20/B-cells** - **Specific Depletion Mechanisms** - **Study Type and Mechanistic Data** - **Mechanistic Content Present** - **CD20/B-cell Relevance** - **Study Rigor and Detail** ## Data extraction We asked a large language model to extract each data column below from each paper with specific instructions for each column. ### Results #### Characteristics of Included Studies | Study | Full text retrieved? | Study focus | Key features | | --- | --- | --- | --- | | J. Uchida et al., 2004 | Yes | Mouse model of anti-CD20 therapy | Developed mouse anti-mouse CD20 antibody panel to study B-cell depletion mechanisms | | B. Cree et al., 2025 | Yes | Review of anti-CD20 antibody evolution | Comprehensive comparison of ocrelizumab, ofatumumab, ublituximab, and rituximab | | Pacheco-Fernández et al., 2018 | No | In vitro CDC comparison | Compared ofatumumab and ocrelizumab CDC activity using B-cell lines | | Samantha Ho et al., 2023 | Yes | B-cell regulating factors | Examined effects on BAFF-APRIL system over 2.5 years | | Schneider-Hohendorf et al., 2025 | No | B- and T-cell receptor repertoires | Analyzed adaptive immune changes in 35 MS patients on ocrelizumab | | Alice Willison et al., 2025 | Yes | Immune cell dynamics comparison | Compared ocrelizumab (n=34) and ofatumumab (n=25) with flow cytometry | | A. Bar-Or et al., 2021 | Yes | Clinical perspectives review | Detailed molecular and pharmacological attributes of four anti-CD20 antibodies | | Darius Häusler et al., 2018 | Yes | EAE model of B-cell recovery | Characterized B-cell depletion and reconstitution in murine MS model | | S. A. Kornilov et al., 2024 | No | Multi-omic characterization | Analyzed plasma proteome, metabolome, and lipidome changes in 14 RRMS patients | | Prajita Paul et al., 2025 | No | Dual-expressor lymphocytes | Identified novel TCR/IgM dual-expressor cells susceptible to anti-CD20 therapy | ## Mechanisms of CD20 Targeting and B-cell Depletion ### CD20 Binding Characteristics Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its added effector function. ### Cytotoxic Mechanisms Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. The antibody exhibits two- to five-fold greater ADCC activity compared to rituximab, while demonstrating three- to five-fold lower CDC activity. Studies in mouse models demonstrated that B-cell depletion is completely dependent on effector cell Fc receptor expression with monocytes serving as the dominant effector cells. ## Patterns of B-cell Depletion ### B-cell Subpopulations Ocrelizumab targets CD20-positive B cells, resulting in significant reductions across multiple B-cell subsets including naive B cells, memory B cells, transitional B cells, and plasmablasts. Plasma cells, which lack CD20 expression, remain resistant to depletion, as do CD20-negative B-cell precursors and hematopoietic stem cells. ### Anatomical Compartments B-cell depletion occurs across multiple anatomical compartments but with varying efficiency. In blood, depletion is nearly complete, with more than 95% reduction in circulating B cells. However, B cells in lymphatic organs and the CNS are not depleted to the same extent. ## Kinetics of Depletion and Recovery ### Recovery Patterns B-cell recovery demonstrates complex kinetics varying by anatomical compartment and B-cell phenotype. In mouse models, bone marrow and spleen show simultaneous recovery, with B cells reappearing at 6 weeks and fully restored by 9 weeks, substantially preceding reappearance in blood. In humans, B-cell levels increase to baseline or the lower limit of normal in 90% of patients within 2.5 years. # Comparative Analysis with Other Anti-CD20 Antibodies Ocrelizumab exhibits distinct mechanistic properties compared to other anti-CD20 antibodies. The enhanced ADCC activity of ocrelizumab, achieved through amino acid engineering, is two- to five-fold greater than rituximab, while its CDC activity is three- to five-fold lower. This mechanistic profile has clinical implications, as ADCC-mediated depletion is associated with fewer infusion-related reactions compared to CDC-mediated pathways. ## Secondary Effects on Immune Regulation Ocrelizumab treatment induces profound changes in the BAFF/APRIL system. Treatment persistently enhances BAFF levels while reducing the endogenous soluble receptor and decoy sTACI. # Synthesis The mechanism by which ocrelizumab drives B-cell depletion involves multiple coordinated processes that vary by context, anatomical location, and B-cell phenotype. ## Acknowledgements The authors thank all contributors for their support in this research.